[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100641898":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":28,"centralContacts":29,"locations":38,"responsibleParty":158,"collaborators":28,"id":160,"slug":161,"hasResults":162,"nctId":163,"briefTitle":164,"officialTitle":165,"acronym":166,"eligibilityCriteria":167,"healthyVolunteers":162,"sex":168,"minAge":169,"maxAge":28,"enrollmentInfo":170,"targetDuration":28,"studyType":173,"phases":174,"briefSummary":176,"conditions":177,"keywords":28,"overallStatus":41,"whyStopped":28,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":188},{"fullName":5,"class":6},"Verastem, Inc.","INDUSTRY",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"VS-7375 Monotherapy 2L\u002F3L","EXPERIMENTAL","2L\u002F3L VS-7375 dose",[13],"Drug: VS-7375",{"label":15,"type":10,"description":16,"interventionNames":17},"VS-7375 Monotherapy 2L\u002F3L Preferred Dose","2L\u002F3L Preferred VS-7375 dose",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"2L-4L with brain metastasis","2L-4L VS-7375 dose",[13],[23],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":28},"DRUG","VS-7375","Taken by mouth",[19,9,15],null,[30,35],{"name":31,"role":32,"phone":33,"phoneExt":28,"email":34},"Verastem Call Center","CONTACT","7812924204","VS-7375-202TrialSupport@verastem.com",{"name":36,"role":32,"phone":28,"phoneExt":28,"email":37},"Ting Wu, MD","VS-7375-202Medical@verastem.com",[39,61,74,91,108,123,139],{"facility":40,"status":41,"city":42,"state":43,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"START LA","RECRUITING","Los Angeles","California","90025","United States","US",{"type":48,"coordinates":49},"Point",[50,51],-118.24368,34.05223,{"lat":51,"lon":50},[54,58],{"name":55,"role":32,"phone":56,"phoneExt":28,"email":57},"Hope Team Distribution List","4244651820","hopeteam@startresearch.com",{"name":59,"role":60,"phone":28,"phoneExt":28,"email":28},"Navid Hafez, MD","PRINCIPAL_INVESTIGATOR",{"facility":62,"status":41,"city":42,"state":43,"zip":63,"country":45,"countryCode":46,"cosmosGeoPoint":64,"geoPoint":66,"contacts":67},"Valkyrie Clinical Trials","90067",{"type":48,"coordinates":65},[50,51],{"lat":51,"lon":50},[68,72],{"name":69,"role":32,"phone":70,"phoneExt":28,"email":71},"Matthew Nguyen","424 535 1874","Matthew.nguyen@vctcare.com",{"name":73,"role":60,"phone":28,"phoneExt":28,"email":28},"David Berz, MD",{"facility":75,"status":41,"city":76,"state":77,"zip":78,"country":45,"countryCode":46,"cosmosGeoPoint":79,"geoPoint":83,"contacts":84},"Emory Winship Cancer Institute","Atlanta","Georgia","30322",{"type":48,"coordinates":80},[81,82],-84.38798,33.749,{"lat":82,"lon":81},[85,89],{"name":86,"role":32,"phone":87,"phoneExt":28,"email":88},"Lily Goggans","404-778-5087","lily.goggans@emory.edu",{"name":90,"role":60,"phone":28,"phoneExt":28,"email":28},"Jennifer Carlisle, MD",{"facility":92,"status":41,"city":93,"state":94,"zip":95,"country":45,"countryCode":46,"cosmosGeoPoint":96,"geoPoint":100,"contacts":101},"START New Jersey","East Brunswick","New Jersey","08816",{"type":48,"coordinates":97},[98,99],-74.41598,40.42788,{"lat":99,"lon":98},[102,106],{"name":103,"role":32,"phone":104,"phoneExt":28,"email":105},"Emily Lichtenstein","7324264750","emily.lichtenstein@startresearch.com",{"name":107,"role":60,"phone":28,"phoneExt":28,"email":28},"Bruno Fang, MD",{"facility":109,"status":41,"city":110,"state":110,"zip":111,"country":45,"countryCode":46,"cosmosGeoPoint":112,"geoPoint":116,"contacts":117},"Memorial Sloan Kettering Cancer Center","New York","10065",{"type":48,"coordinates":113},[114,115],-74.00597,40.71427,{"lat":115,"lon":114},[118,121],{"name":119,"role":32,"phone":28,"phoneExt":28,"email":120},"Robert Dyson","dysonr@mskcc.org",{"name":122,"role":60,"phone":28,"phoneExt":28,"email":28},"Kathryn Arbour, MD",{"facility":124,"status":41,"city":125,"state":126,"zip":127,"country":45,"countryCode":46,"cosmosGeoPoint":128,"geoPoint":132,"contacts":133},"START Fort Worth","Fort Worth","Texas","76104",{"type":48,"coordinates":129},[130,131],-97.32085,32.72541,{"lat":131,"lon":130},[134,137],{"name":135,"role":32,"phone":136,"phoneExt":28,"email":57},"Hope Team","6823503010",{"name":138,"role":60,"phone":28,"phoneExt":28,"email":28},"Salwan Almutar, MD",{"facility":140,"status":41,"city":141,"state":142,"zip":143,"country":144,"countryCode":145,"cosmosGeoPoint":146,"geoPoint":150,"contacts":151},"ICON Cancer Centre South Brisbane","Brisbane","Queensland","4101","Australia","AU",{"type":48,"coordinates":147},[148,149],153.02809,-27.46794,{"lat":149,"lon":148},[152,156],{"name":153,"role":32,"phone":154,"phoneExt":28,"email":155},"Apryl Chelin","07 3737 4757","Apryl.chelin@icon.team",{"name":157,"role":60,"phone":28,"phoneExt":28,"email":28},"Jermaine Coward, MD",{"type":159,"investigatorFullName":28,"investigatorTitle":28,"investigatorAffiliation":28,"oldNameTitle":28,"oldOrganization":28},"SPONSOR","100641898","a-phase-2-study-of-vs-7375-in-patients-with-kras-g12d-mutated-non-small-cell-lung-cancer-100641898",false,"NCT07659782","A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer","A Phase 2, Open-label Study of VS-7375, an Oral KRAS G12D (ON\u002FOFF) Inhibitor, in Patients With Previously Treated, Advanced KRAS G12D-Mutated Non-Small Cell Lung Cancer (TARGET-D 202)","TARGET-D 202","Inclusion Criteria:\n\n* Histopathology confirmed unresectable locally advanced or metastatic NSCLC\n* Measurable disease per RECIST 1.1\n* Local testing confirmed KRAS G12D mutation (tissue required for confirmatory central testing)\n* ECOG PS=0 or 1\n* Adequate organ function\n* Received prior treatment with a platinum-based chemotherapy regimen and an immune checkpoint inhibitor in the advanced, non-resectable setting.\n* Have documented disease progression during or following their most recent prior line of therapy.\n\nPatients with 2L\u002F3L on stable or preferred dose:\n\n* Received at least 1 and no more than 2 prior systemic lines of therapy for advanced (in the unresectable locally advanced or metastatic setting) NSCLC.\n\nPatients with 2L-4L with brain metastases:\n\n* Received at least 1 and no more than 3 prior systemic lines of therapy for advanced (in the unresectable locally advanced or metastatic setting) NSCLC.\n* Have asymptomatic and untreated brain metastases\n* At least 1 untreated measurable brain lesion per mRECIST v1.1 with a long axis ≥ 0.5 cm and ≤ 3 cm.\n\nExclusion Criteria:\n\n* Have any other documented co-existing common RAS mutation(s)\n* Prior anti-cancer Tx within 4 weeks or drug-specific timeline within first treatment dose, whichever shorter\n* Major surgery within 4 weeks of first treatment dose\n* Radiation therapy (RT) within 1 week of first treatment dose\n* History of drug-induced Interstitial Lung Disease\n* Receipt of prior direct RAS inhibitor\n* Untreated or symptomatic CNS metastasis\n* Receipt of strong CYP3A4 inhibitor\u002Finducer or CYP3A4 sensitive substrates with narrow therapeutic index within 14 days or drug-specific timeline within first treatment dose, whichever is shorter\n* Receipt of PPI or H2 blocker within 5 days\n* Inability to swallow oral medication\n* Other protocol-defined inclusion\u002Fexclusion criteria may apply","ALL","18 Years",{"count":171,"type":172},105,"ESTIMATED","INTERVENTIONAL",[175],"PHASE2","This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab in patients with metastatic KRAS G12D - mutated Non-Small Cell Lung Cancer",[178],"Non-Small Cell Lung Cancer","2026-08-19",{"date":181,"type":182},"2026-08-20","ACTUAL",{"date":184,"type":182},"2026-07-22",{"date":186,"type":172},"2028-12",{"name":5,"class":6},7]